Pipeline

Global
Rights
Program
Potential
Indications
Preclinical
Discovery
Lead Optimisation
CTA-enabling
Clinical
Phase 1
Phase 2
Phase 3
Expected Milestones
GPR84 Antagonist
  • Metabolic Disease
  • NASH/NAFLD

Phase I study completed in 2024. Phase Ib/IIa underway

OXER1 Antagonist
  • Eosinophilic-Driven Asthma
  • Atopic Dermatitis

Lead Candidate nominated

GPR40 Agonist
  • Insulin Resistance/Diabetes

Discovery Stage